Products for Research Use Only

AM-36

CAT: 0804-HY-114659Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-114659Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
AM-36 is a neuroprotective agent with combined antioxidant and sodium channel blocking actions. AM-36 can inhibit cell apoptosis and ROS prodiction. AM-36 can reduce neuronal damage and DA release after middle cerebral artery occlusion in rats. AM-36 can be used for the researches of inflammation and neurological disease, such as stroke[1][2][3].
CAS Number
199467-52-2
UNSPSC
12352005
Target
Apoptosis; Reactive Oxygen Species (ROS) ; Sodium Channel
Related Pathways
Apoptosis; Immunology/Inflammation; Membrane Transporter/Ion Channel; Metabolic Enzyme/Protease; NF-κB
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology; Neurological Disease
Smiles
ClC1=CC=C(C(CN2CCN(CC2)CC3=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C3)O)C=C1
Molecular Formula
C27H39ClN2O2
Molecular Weight
459.06
References & Citations
[1]Callaway JK, et al. Delayed treatment with AM-36, a novel neuroprotective agent, reduces neuronal damage after endothelin-1-induced middle cerebral artery occlusion in conscious rats. Stroke. 1999 Dec;30 (12) :2704-12; discussion 2712.|[2]Callaway JK, et al. Incorporation of sodium channel blocking and free radical scavenging activities into a single drug, AM-36, results in profound inhibition of neuronal apoptosis. Br J Pharmacol. 2001 Apr;132 (8) :1691-8.|[3]Callaway JK, et al. AM-36, a novel neuroprotective agent, profoundly reduces reactive oxygen species formation and dopamine release in the striatum of conscious rats after endothelin-1-induced middle cerebral artery occlusion. Neuropharmacology. 2003 May;44 (6) :787-800.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported